Pancreatic cancer chemo can trigger resistance; blocking the cause worked in mice
Pancreatic cancerPart of a story we are following · 4 articles · See every update
If you or someone you love is being treated for pancreatic cancer, this finding has two sides. A standard chemotherapy combination can change the tissue around a tumor in ways that help the cancer resist the drugs. Scientists also found the cell type behind it, and removing it in mice made the treatment work better. This has not been tested in people yet.
In a study of tumors from patients with pancreatic cancer, plus experiments in mice, researchers found that albumin-bound paclitaxel given with gemcitabine pushed support cells around the tumor into a state linked to chemo resistance. A newly identified group of these cells was more common in patients whose tumors did not respond.
How the study worked
Researchers looked at individual cells inside tumors from patients treated before surgery with albumin-bound paclitaxel plus gemcitabine, then ran lab and mouse experiments to learn why some tumors stopped responding. The study was published in Science Translational Medicine on November 11, 2026. The abstract does not give patient numbers, and the idea of removing the problem cells has only been tried in mice.
What are cancer-associated fibroblasts?
A tumor is not just cancer cells. It sits in a neighborhood of other tissue, called the stroma. Some of the most common residents are support cells called cancer-associated fibroblasts, or CAFs. Think of them as the crew around a building site. They can build walls, send signals and shape what happens inside.
CAFs come in different states. Two matter here. One is a firm, scaffold-building state. The other is an inflammatory state that sends out more chemical messages.
What they found
The chemo combination is a standard first treatment for pancreatic tumors that are borderline resectable (hard to remove with surgery) or locally advanced. But the cancer often stops responding to it later, and until now the reasons were poorly understood.
Here is what the team learned:
- The chemo changed the neighborhood. In patient tumors, treatment moved many CAFs from the scaffold-building state to the inflammatory state.
- A new troublemaker turned up. The team identified a previously unrecognized group of CAFs marked by a protein called TMEM100. These cells were more common in patients who did not respond to treatment.
- The drug helped create them. Albumin-bound paclitaxel switched on a signaling pathway (IL-2-STAT5) that drives the TMEM100 protein.
- They protect the cancer. TMEM100 cells release a signal molecule called amphiregulin. It switches on a growth pathway (EGFR) in the tumor cells, and that helps them resist chemo.
- Removing them helped in mice. When the researchers genetically removed these cells in mouse models, the CAFs stopped switching states and the chemo worked better against the tumors.
The authors describe these cells as a promising target to make pancreatic tumors more sensitive to treatment given before surgery.
What is still unknown is whether a safe drug can target these cells in people, and whether doing so would help patients live longer. Those questions need new studies.
What you can do today
This finding does not change current treatment advice. The chemo combination remains a standard first approach, and nothing here says to stop or alter it. If you or a family member is in treatment, keep following the plan your care team set. If you would like to know more, write down one question, such as how your team checks whether treatment is still working, and bring it to your next appointment.
For clinicians and researchers
Design: Translational study combining single-cell transcriptomics of patient pancreatic ductal adenocarcinoma tumors treated with neoadjuvant albumin-bound paclitaxel plus gemcitabine (AG), mechanistic experiments and mouse models. Patient n, follow-up and comparator are not given in the abstract.
Main result: AG treatment was associated with a switch of cancer-associated fibroblasts from myofibroblastic to inflammatory states and with a TMEM100+CAF subset enriched in nonresponders. Genetic ablation of TMEM100+CAFs in mice reversed CAF switching and enhanced AG efficacy.
Main limitation: Causal evidence for the TMEM100-AREG resistance axis comes from mouse models and mechanistic experiments; the patient single-cell data are descriptive, and no effect sizes or sample sizes are reported in the abstract.
Open question: Whether targeting TMEM100+CAFs, or the AREG-EGFR signaling they activate, can sensitize pancreatic tumors to neoadjuvant AG in patients remains to be tested.
Cite this article
Mongevity Desk. Pancreatic cancer chemo can trigger resistance; blocking the cause worked in mice. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/pancreatic-cancer-chemo-resistance-target-mice/Mongevity Desk. Pancreatic cancer chemo can trigger resistance; blocking the cause worked in mice [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/pancreatic-cancer-chemo-resistance-target-mice/Mongevity Desk. (2026, November 22). Pancreatic cancer chemo can trigger resistance; blocking the cause worked in mice. Mongevity. https://mongevity.science/cancer/2026/11/pancreatic-cancer-chemo-resistance-target-mice/
<a href="https://mongevity.science/cancer/2026/11/pancreatic-cancer-chemo-resistance-target-mice/">Pancreatic cancer chemo can trigger resistance; blocking the cause worked in mice</a>
Free to share or quote with credit and a link.
Questions and answers
- Does this mean chemo for pancreatic cancer does not work?
- No. The combination is still a standard first treatment. The study shows one way tumors can become resistant to it over time.
- Is there a treatment that targets these cells now?
- Not yet. Removing the cells worked in mice. It has not been tested in people, so it is not an available treatment.
- What is TMEM100?
- It is a protein found in a newly identified group of support cells around pancreatic tumors. These cells were more common in patients who did not respond to chemo.
- Should I change my treatment because of this study?
- No. Current advice does not change. Keep following your care team's plan and bring any questions to your appointments.


